Cometriq
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Exelixis launched its first drug, the oral tyrosine kinase inhibitor Cometriq (cabozantinib), for treating patients with…
Exelixis launched its first drug, the oral tyrosine kinase inhibitor Cometriq (cabozantinib), for treating patients with…
Exelixis launched its first drug, the oral tyrosine kinase inhibitor Cometriq (cabozantinib), for treating patients with…